Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial

Carlos M. Campos, Bojan M. Stanetic, Vasim Farooq, Simon Walsh, Yuki Ishibashi, Yoshinobu Onuma, Hector M. Garcia-Garcia, Javier Escaned, Adrian Banning, Patrick W. Serruys

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

29 Citations (Scopus)

Abstract

Background Heart Team (HT) and the SYNTAX Score II (SSII) have been integrated to the contemporary guidelines with the aim to provide a multidisciplinary decision-making process between coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI). Aims To prospectively assess the agreement between the HT decision and the SSII recommendation regarding the revascularization strategy in patients with 3-vessel coronary artery disease (CAD) of the SYNTAX II trial. Methods The SSII predicts the 4-year mortality of an individual patient both after PCI and after CABG. Patients were treated by PCI when the SSII predicted a mortality risk favoring PCI or when risk predictions were equipoise between PCI and CABG. However, the HT could overrule the SSII and recommend either CABG or PCI. Results A total of 202 patients have been screened and 24 did not fulfill inclusion criteria. The median age was 67.0 (IQR 59.0-73.3), and 167 (82.7%) were male. The HT endorsed SSII treatment recommendation, for CABG or PCI, in 152 patients (85.4%). Three patients had preference for PCI, irrespective of the HT decision. The main reason for the HT to overrule the SSII and recommend CABG was the prospect of a more complete revascularization (21 of 25 patients). Patients recommended for CABG by the HT had significantly higher anatomical SYNTAX score (P = 0.03) and higher predicted mortality risk for PCI (P = 0.04) when compared with patients that were enrolled in the trial. Conclusion The SYNTAX score II showed to be a suitable tool for guiding treatment decisions of patients with 3-vessel coronary artery disease being endorsed by the HT in the vast majority of the patients that have been enrolled in the SYNTAX II trial.

Original languageEnglish
Pages (from-to)E229-E238
JournalCatheterization and Cardiovascular Interventions
Volume86
Issue number6
DOIs
Publication statusPublished - 15 Nov 2015
Externally publishedYes

Keywords

  • coronary artery disease
  • drug eluting
  • risk stratification
  • stent

Fingerprint

Dive into the research topics of 'Risk stratification in 3-vessel coronary artery disease: Applying the SYNTAX Score II in the Heart Team Discussion of the SYNTAX II trial'. Together they form a unique fingerprint.

Cite this